818 Breakthrough Technology | Integrated Culture Protocol for γδ T Cells
Release Date:
2026-03-16 16:46
Quality First, Innovation-Based
Strategic Choices for Breaking the Impasse Through Differentiation in the Compliance Era
01. Policy Orientation: Track Selection Determines Success or Failure
The implementation of the “818 Regulations” marks the official entry of China’s cell therapy industry into a new phase of standardized development, one that prioritizes clinical efficacy as the benchmark for value, enforces rigorous compliance across the entire value chain as an inviolable baseline, and places differentiated technological innovation at the core of its growth engine. The Regulations explicitly restrict low-level duplication and homogeneous competition, while giving priority to the translation of technology pathways that demonstrate clear clinical value and outstanding scientific innovation, thereby establishing clear compliance boundaries and innovation-oriented guidance for the industry’s future development.
Meanwhile, the currently highly acclaimed umbilical cord blood–derived NK cell therapy suffers from severe homogenization and faces multiple developmental bottlenecks. Research data indicate that, following cryopreservation and thawing, NK cells generally exhibit an irreversible decline in their tumor-killing activity, and therapeutic efficacy varies substantially among individuals, making it difficult to establish stable, reproducible clinical evidence. This significantly increases the uncertainty and risk of failure in clinical translation.
02. Comprehensive Performance Leadership, Creating New Value in Combination Therapy
As a next-generation allogeneic immune cell, γδ T cells not only demonstrate superior performance compared with NK cells in monotherapy but also synergize with NK cells to establish an innovative combination therapy strategy that achieves “rapid, short-term tumor clearance combined with long-term immune protection.” This approach holds promise for overcoming the efficacy limitations of single-cell therapies at the mechanistic level and is highly aligned with the regulatory philosophy advocated by the “818 Regulations,” which emphasizes both compliance and innovation. γδ T cells possess dual characteristics of innate and adaptive immunity; their antitumor activity, in vivo persistence, and formulation stability all outperform those of NK cells. These advantages have been substantiated by evidence from top international journals, thereby comprehensively addressing the core regulatory concerns regarding efficacy and safety.
Stable cryopreservation with controllable quality ：
Following cryopreservation and thawing, γδ T cells exhibit no significant loss of tumor-killing activity, thereby effectively ensuring batch-to-batch consistency of the final product and precisely addressing the core challenge of reduced NK cell activity after cryopreservation.
Stable therapeutic efficacy, overcoming individual variability ：
Clinical data have demonstrated that the in vivo antitumor activity of γδ T cells is markedly superior to that of NK cells; their cytotoxic effect is MHC-independent, unaffected by donor–recipient genetic disparities, and capable of delivering consistent clinical efficacy, thereby providing robust support for achieving the primary efficacy endpoints in clinical trials.
Long-lasting persistence, establishing immune memory ：
γδ T cells can achieve long-term expansion and persistence in patients, continuously secreting key cytokines such as IFN-γ to activate and sustain a durable anti-tumor immune response. Notably, following CAR modification, CAR-γδ T cells exhibit sustained cytotoxic activity against tumor cells, with clinical benefit potential that far exceeds that of CAR-NK cells.
NK+γδT Combination Therapy ：
Synergistic enhancement to achieve clinical breakthroughs that deliver “1+1>2”
1. Spatiotemporal synergy and complementary advantages NK cells achieve rapid tumor clearance within 2 hours, while γδ T cells, with their long-lasting persistence, provide continuous surveillance and suppress tumor growth to prevent recurrence, thereby establishing a comprehensive therapeutic loop that encompasses both acute cytotoxicity and long-term disease control.
2. Broader antigen coverage to enhance response rates: Combined application can effectively overcome tumor heterogeneity, broaden the scope of targeted therapy, and significantly enhance both the treatment response rate and the overall efficacy.
3. Enhanced security and controllable risks Both NK cells and γδ T cells are mature, versatile immune cell types; monotherapy has demonstrated a favorable safety profile, and their combined use does not introduce additional safety risks, with overall safety being manageable and predictable.
Differentiated positioning to build technological barriers. : By sidestepping the “involutionary” competition in NK-cell therapy, we will build a robust technological moat centered on γδ T cells, gain pricing autonomy, and seize the commanding height of next-generation immune cell therapies.
03. Evidence-based support from top-tier journals strengthens the scientific foundation.
Subjournal of Science: γδ T-cell infiltration is significantly positively correlated with breast cancer survival.
Studies have demonstrated that the density of γδ T-cell infiltration in breast cancer tissues is significantly positively correlated with patients’ overall survival—specifically, the higher the proportion of γδ T cells in the tumor microenvironment, the greater the survival benefit. This finding not only underscores the critical role of γδ T cells in solid-tumor immunity but also offers novel therapeutic strategies for refractory subtypes such as triple-negative breast cancer, thereby providing an important evidence-based foundation for clinical exploration of NK+γδ T–based combination therapies in the field of breast cancer.
Landmark Study in Cell: NK+γδT Combination Strategy Achieves Breakthrough Efficacy in Cholangiocarcinoma
A clinical study published in Cell has demonstrated that, in refractory cholangiocarcinoma with a notoriously poor prognosis, combined NK cell–γδ T cell therapy exhibits distinct advantages: NK cells rapidly eliminate tumor cells, while γδ T cells persist long-term to sustain immune surveillance, thereby establishing a therapeutic feedback loop of “acute cytotoxicity plus durable immunosurveillance.” This study provides high-level evidence supporting the clinical translation of this combination regimen in solid tumors and fully aligns with the stringent requirements of the “818 Regulations” regarding the scientific rationale and innovative value of clinical research.
04. Now is the Right Time for Differentiated Deployment
Currently, global research and development of γδ T-cell therapy remains in its early stages, with most registered clinical trials concentrated in Phase I, and no monopolistic market structure has yet emerged. Meanwhile, NK cell–γδ T-cell combination therapy, as an emerging therapeutic approach, offers substantial room for innovation and significant clinical potential, aligning closely with current policy priorities.
In China, γδ T-cell therapy has already drawn leading companies such as Senlang Bio, Qinghui Liannuo, Baiji Gene, Legend Biotech, Bosunji, WuXi AppTec Jeno, Shanghai Cell Therapy Group, Jide Kangmin, and Ruichuang Bio to invest and develop in this field, driving sustained growth in industry enthusiasm. Compared with the highly competitive and homogenized NK-cell therapy, γδ T-cell monotherapy and combination regimens feature higher technical barriers and a more favorable competitive landscape, making them a key pathway for achieving differentiation and breaking through market saturation.
Integrated Culture Protocol for γδ T Cells
Guided by the R&D philosophy of “end-to-end process optimization” and “a triad of technologies,” HeyouSheng Biotechnology has launched a benchmark one-stop culture solution for immune cells and stem cells. This solution integrates compliant seed cells, HiXpan Registered trademark Serum-free culture kit, HiXpan Registered trademark Our four core products—cell culture supplements and Cell Feeder底透 cell culture flasks—form a comprehensive, high-efficiency, integrated cell culture system, helping customers achieve standardized and compliant operations across the entire R&D-to-translational pipeline.
In the field of γδT cell culture, HeyouSheng provides end-to-end professional support: from preliminary screening and collection of ethically compliant γδT super-donors at the front end, to integration with HiXpan. Registered trademark γδ T cell serum-free culture kit, HiXpan Registered trademark An integrated culture system that combines cell culture supplements with Cell Feeder底透 cell culture flasks, comprehensively enhancing cell preparation efficiency and process robustness, thereby providing reliable support for innovation in cell therapy and its clinical translation.
Integrated Culture Data Presentation for γδ T Cells
The initial inoculum was 7.5 × 10^7 cells, and the cell count on Day 7 was 6 × 10^8. Three groups were established, with 5 × 10^7, 1 × 10^8, and 1 × 10^8 cells, respectively, and continued to be cultured for another 7 days until Day 14:
In summary, γδ T cells are cultured using the HeyouSheng Cell Feeder bottom-permeable cell culture flask:
Higher expansion efficiency: Compared with conventional culture bags, the total fold expansion of γδ T cells over the subsequent 7 days increases by 1.1- to 1.73-fold, yielding a greater number of highly active cells and significantly reducing the per-cell cultivation cost.
Under identical conditions, cell culture flasks with a Cell Feeder bottom membrane yield better expansion results when seeded at lower densities.
Contact Information
For more details on the integrated culture protocol for HeYouSheng γδ T cells, application data, or to request a trial, please contact our sales representative, Mr. Xie, at 15201775322. Alternatively, scan the QR code below to receive end-to-end technical guidance from our experts.
Related News
This training program focuses on the regulatory standards governing the manufacturing of cell therapy products and the clinical research and translational applications of cutting-edge biomedical technologies, attracting participants from enterprises, research institutes, clinical institutions, and industry-chain representatives across the country. Standardization is the fundamental cornerstone for ensuring that these products are safe, effective, and accessible. As a one-stop upstream cell solutions provider offering primary cell services, pharmacological efficacy services, and product services, Heyousheng looks forward to engaging in in-depth exchanges with industry experts and peers.
3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 3: CBNK Competitor Comparison
HeYouSheng Bio’s 3.0 High-Efficiency HiXpan® NK Serum-Free Culture Kit is manufactured in strict compliance with GMP standards, and its production system adheres to relevant guidelines, including the “818 Requirements,” making it suitable for pharmaceutical-grade manufacturing and applications. In response to extensive customer demand, we have conducted a comparative analysis of culture performance against two leading commercial competitor media.
3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 2: PBNK Derived from Peripheral Blood
HeYouSheng Biotechnology’s newly launched 3.0 High-Efficiency Serum-Free NK Cell Culture Kit (Catalog No.: NK888-2L), in collaboration with the PBMC Seed Bank, provides a comprehensive, integrated cell culture solution: from thawing and recovering PBMC seed stocks or directly and efficiently expanding fresh PBMCs, to ultimately obtaining NK cells with high purity and high viability.
HeYouSheng Biotechnology, in collaboration with Boteng Biotechnology, has pioneered the launch of PBMCs that comply with both GMP standards and the dual China–U.S. regulatory submission requirements, thereby establishing a robust compliance foundation for iPSC reprogramming right at the source. The notion of “starting from ‘zero’” not only signifies the proactive avoidance of compliance risks from the very outset of R&D, but also reflects the establishment by the two companies of a comprehensive, end-to-end compliance closed-loop that spans the entire process—from donor screening and sample collection to isolation, preparation, and quality control.
818 Breakthrough Technology | Integrated Culture Protocol for γδ T Cells
The implementation of the “818 Regulations” marks the official entry of China’s cell therapy industry into a new phase of standardized development, one that prioritizes clinical efficacy as the benchmark for value, upholds rigorous compliance across the entire process as an inviolable baseline, and centers on differentiated technological innovation as the core driver. The Regulations explicitly restrict low-level duplication and homogeneous competition, while giving priority to the translation of technology pathways that demonstrate clear clinical value and outstanding scientific innovation, thereby establishing clear compliance boundaries and innovation-oriented guidance for the future direction of the industry.
Conference Announcement | Hycells cordially invites you to join the 3rd Boao Lecity Stem Cell Summit
From March 20 to 22, 2026, the Third Boao Lecity Stem Cell Conference, co-hosted by the China Anti-Aging Promotion Association and Hainan University, will be held in Boao Lecity, Hainan. With the theme “Cell Therapy Pioneering the Third Medical Revolution,” the conference will also make a major announcement of the latest batch of cell therapy procedures that are now permitted to be billed, thereby establishing an international high-end platform that brings together cutting-edge ideas, translates research into clinical practice, fosters industry collaboration, and jointly develops policies and standards.